Prosecution Insights
Last updated: November 20, 2026

Michael J Schmitt, USPTO Patent Examiner

Listed by the USPTO as SCHMITT, MICHAEL J

Tech Center 1600 • Art Units: 1629

This examiner grants 57% of resolved cases

Analysis

SCHMITT, MICHAEL J has 664 resolved cases in Tech Center 1600 and Art Unit 1629. The allowance rate is 56.9%, the interview lift is 19.9%, and the median time to allowance is 1041 days. The case volume provides a substantial record, with allowance outcomes forming more than half of the resolved matters.

The listed companies are Mirati Therapeutics Inc., Mayo Foundation for Medical Education and Research, and Virginia Polytechnic Institute and State University. The listed firms are CANTOR COLBURN LLP, Casimir Jones, S.C., and COOLEY LLP. The interview lift is a modest additional signal, so practitioners can consider interviews without assuming they substitute for a strong written record. The median duration should inform portfolio timing and client counseling.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

56.9%
Allow Rate
-3.1% vs TC avg
704
Total Applications
+19.9%
Interview Lift
1041
Avg Prosecution Days
Based on 664 resolved cases, 2023–2026

Rejection Statute Breakdown

4.0%
§101 Eligibility
15.3%
§102 Novelty
36.9%
§103 Obviousness
21.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18694921 COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SHP-2 INHIBITORS Non-Final OA MIRATI THERAPEUTICS, INC.
18848249 METHODS AND MATERIALS FOR TREATING PANCREATIC DISEASES AND DISORDERS Non-Final OA MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
18560282 COMBINATIONS FOR TREATMENT OF CANCER Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
18847164 SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE Non-Final OA PURDUE RESEARCH FOUNDATION
18853520 COMBINATION THERAPY FOR TREATING CANCER Non-Final OA AstraZeneca AB
18796015 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF Non-Final OA Arizona Board of Regents on Behalf of the University of Arizona
18806178 BI-FUNCTIONAL MOLECULES TO DEGRADE CIRCULATING PROTEINS Non-Final OA Yale University
18272486 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING OR AMELIORATING NONALCOHOLIC FATTY LIVER DISEASE AND RELATED DISEASES OR DISORDERS Non-Final OA Thomas Jefferson University
18188943 Metabolic Markers of Attention Deficit Hyperactivity Disorder Final Rejection Laboratory Corporation of America Holdings
18005269 METHODS OF TREATING PROTEINOPATHIES Final Rejection Woolsey Pharmaceuticals, Inc.
17113571 METHODS OF TREATING CHEMOTHERAPY OR RADIOTHERAPY INDUCED NEUTROPENIA Final Rejection HANMI PHARM. CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Michael J Schmitt's allowance rate?

56.9% of resolved applications examined by Michael J Schmitt were allowed (664 resolved cases), compared with 42.4% across Art Unit 1629 over the last five years.

Does an interview help with examiner Michael J Schmitt?

This examiner's interview lift is +19.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Michael J Schmitt take to allow a patent?

Applications allowed by Michael J Schmitt took 1,041 days on average from filing to allowance.

Which art unit does examiner Michael J Schmitt work in?

Michael J Schmitt examines applications in Art Unit 1629 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month